Partner Carl Hittinger was quoted in a May 24, 2023, Daily Journal article titled “Illumina case setting up constitutional battle over FTC power.” The piece examines the proposed acquisition of Grail Inc. (a company that makes blood tests to detect cancer) by Illumina Inc., a biotech company.
The article focuses on whether the Federal Trade Commission is empowered to block the deal. Hittinger characterizes the FTC’s authority in this case as “a tough sell,” and he notes that the choice of the Fifth Circuit was a good one for Illumina, as the appellate court is widely regarded as the nation’s most conservative, according to the article.